A carregar...
CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
The targeted treatment of advanced non-small cell lung cancer (NSCLC) harboring genomic rearrangement of ALK is a paradigm for personalized oncology. More than 15 different ALK fusion partners have been discovered in NSCLC patients. Most of these ALK fusions responded well to the ALK inhibitor crizo...
Na minha lista:
| Publicado no: | Cancer Biol Ther |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6301797/ https://ncbi.nlm.nih.gov/pubmed/30273505 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1480282 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|